Antiplatelet effect of butylidenephthalide.
Butylidenephthalide inhibited, in a dose-dependent manner, the aggregation and release reaction of washed rabbit platelets induced by collagen and arachidonic acid. Butylidenephthalide also inhibited slightly the platelet aggregation induced by PAF and ADP, but not that by thrombin or ionophore A23187. Thromboxane B2 formation caused by collagen, arachidonic acid, thrombin and ionophore A23187 was in each case markedly inhibited by butylidenephthalide. Butylidenephthalide inhibited the aggregation of ADP-refractory platelets, thrombin-degranulated platelets, chymotrypsin-treated platelets and platelets in the presence of creatine phosphate/creatine phosphokinase. Its inhibition of collagen-induced aggregation was more marked at lower Ca2+ concentrations in the medium. The aggregability of platelets inhibited by butylidenephthalide could be recovered after the washing of platelets. In human platelet-rich plasma, butylidenephthalide and indomethacin prevented the secondary aggregation and blocked ATP release from platelets induced by epinephrine. Prostaglandin E2 formed by the incubation of guinea-pig lung homogenate with arachidonic acid could be inhibited by butylidenephthalide, indomethacin and aspirin. It is concluded that the antiplatelet effect of butylidenephthalide is mainly due to an inhibitory effect on cyclo-oxygenase and may be due partly to interference with calcium mobilization.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D000255:Adenosine Triphosphate / Q000097:blood; D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors; D000001:Calcimycin / Q000494:pharmacology; D003094:Collagen / Q000037:antagonists & inhibitors; D015232:Dinoprostone; D006168:Guinea Pigs; D006801:Humans; D066298:In Vitro Techniques; D010795:Phthalic Acids / Q000494:pharmacology*; D010796:Phthalic Anhydrides / Q000494:pharmacology*; D010972:Platelet Activating Factor; D010974:Platelet Aggregation / Q000187:drug effects*; D011458:Prostaglandins E / Q000096:biosynthesis; D011817:Rabbits; D013917:Thrombin / Q000494:pharmacology; D013929:Thromboxane B2 / Q000096:biosynthesis
D001095:Arachidonic Acids; D001779:Blood Coagulation Factors; D010795:Phthalic Acids; D010796:Phthalic Anhydrides; D010972:Platelet Activating Factor; D011458:Prostaglandins E; D016718:Arachidonic Acid; D000001:Calcimycin; D013929:Thromboxane B2; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D003094:Collagen; D013917:Thrombin; D015232:Dinoprostone; C026105:butylidenephthalide